Geron Corporation (GERN) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Geron Corporation (GERN) Bundle
Gain mastery over your Geron Corporation (GERN) valuation analysis using our sophisticated DCF Calculator! Loaded with accurate (GERN) data, this Excel template enables you to adjust forecasts and assumptions to determine the intrinsic value of Geron Corporation with accuracy.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .5 | .3 | 1.4 | .6 | .2 | .2 | .2 | .1 | .1 | .1 |
| Revenue Growth, % | 0 | -45 | 450.59 | -57.21 | -60.23 | -15.61 | -15.61 | -15.61 | -15.61 | -15.61 |
| EBITDA | -67.8 | -73.9 | -111.6 | -134.2 | -174.8 | -.2 | -.2 | -.1 | -.1 | -.1 |
| EBITDA, % | -14733.04 | -29218.18 | -8010.7 | -22508.56 | -73747.68 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .8 | .9 | .8 | .9 | 1.0 | .2 | .2 | .1 | .1 | .1 |
| Depreciation, % | 168.7 | 369.57 | 56.21 | 145.64 | 435.86 | 91.24 | 91.24 | 91.24 | 91.24 | 91.24 |
| EBIT | -68.5 | -74.9 | -112.4 | -135.0 | -175.8 | -.2 | -.2 | -.1 | -.1 | -.1 |
| EBIT, % | -14901.74 | -29587.75 | -8066.91 | -22654.19 | -74183.54 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 139.6 | 196.6 | 183.7 | 173.1 | 333.7 | .2 | .2 | .1 | .1 | .1 |
| Total Cash, percent | .0 | .1 | .0 | .0 | .1 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .8 | .7 | 1.8 | 3.1 | 1.7 | .2 | .2 | .1 | .1 | .1 |
| Account Receivables, % | 174.35 | 285.38 | 126.56 | 527.52 | 698.31 | 100 | 100 | 100 | 100 | 100 |
| Inventories | -.8 | -.7 | -1.4 | -3.1 | .0 | -.2 | -.1 | -.1 | -.1 | -.1 |
| Inventories, % | -174.35 | -285.38 | -100.43 | -527.52 | 0 | -80 | -80 | -80 | -80 | -80 |
| Accounts Payable | 1.2 | 6.9 | 6.7 | 10.2 | 6.2 | .2 | .2 | .1 | .1 | .1 |
| Accounts Payable, % | 256.74 | 2734.78 | 480.04 | 1709.73 | 2599.58 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.4 | -.4 | -.2 | -.4 | -.8 | -.2 | -.1 | -.1 | -.1 | -.1 |
| Capital Expenditure, % | -89.78 | -158.5 | -14.86 | -72.32 | -350.21 | -75.39 | -75.39 | -75.39 | -75.39 | -75.39 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -63.6 | -74.9 | -117.1 | -134.2 | -175.8 | -.2 | -.2 | -.1 | -.1 | -.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -62.0 | -68.6 | -117.1 | -129.9 | -181.3 | -4.5 | -.2 | -.1 | -.1 | -.1 |
| WACC, % | 6.97 | 7 | 7 | 7 | 7 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -2 | |||||||||
| Present Terminal Value | -1 | |||||||||
| Enterprise Value | -6 | |||||||||
| Net Debt | 16 | |||||||||
| Equity Value | -22 | |||||||||
| Diluted Shares Outstanding, MM | 571 | |||||||||
| Equity Value Per Share | -0.04 |
What You Will Get
- Real Geron Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Geron Corporation’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- 🔍 Real-Life GERN Financials: Pre-filled historical and projected data for Geron Corporation (GERN).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Geron’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Geron’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the prebuilt Excel template with Geron Corporation’s (GERN) data included.
- Step 2: Explore the pre-filled sheets and understand the key metrics.
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Geron Corporation’s (GERN) intrinsic value.
- Step 5: Make informed investment decisions or generate reports using the outputs.
Why Choose Geron Corporation (GERN)?
- Innovative Solutions: Cutting-edge research and development in cancer therapeutics.
- Proven Track Record: A history of successful clinical trials and advancements in treatment.
- Commitment to Patients: Focused on improving patient outcomes through targeted therapies.
- Expert Team: Led by experienced professionals in oncology and pharmaceutical development.
- Strong Partnerships: Collaborations with leading institutions enhance research capabilities.
Who Should Use This Product?
- Investors: Evaluate Geron Corporation’s (GERN) valuation prior to making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and analyze financial forecasts.
- Startup Founders: Understand the valuation strategies of established biotech companies like Geron Corporation.
- Consultants: Create comprehensive valuation reports for your clients focusing on Geron Corporation.
- Students and Educators: Utilize real-time data to teach and apply valuation principles using Geron Corporation as a case study.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Geron Corporation (GERN) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Geron Corporation (GERN).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.